parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in ependymal cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	4 Parkinson's trials, 0 stopped	1.00
literature PubMed	4 Parkinson's papers of 784	0.79
pathways Reactome	13 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 5917

receipt 5925: DLL1 in dopamine neurons, braak

power: full sample -0.21 (p 0.413, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.19 (p 0.455, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.164, n 18). could be the mix.
skeptic: leave-one-out range -0.35 to -0.11, sign flips 0; without severely affected donors -0.21 (p 0.413, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DLL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5924: DLL1 in oligodendrocytes, braak

power: full sample +0.26 (p 0.306, n 18), 95% CI -0.24 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.26 (p 0.306, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.28 (p 0.265, n 18). could be the mix.
skeptic: leave-one-out range +0.15 to +0.34, sign flips 0; without severely affected donors +0.26 (p 0.306, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DLL1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts